TY - JOUR
T1 - Evaluating subject-level incremental values of new markers for risk classification rule
AU - Cai, T.
AU - Tian, L.
AU - Lloyd-Jones, D.
AU - Wei, L. J.
N1 - Funding Information:
Acknowledgments The authors thank the Professor Jianwen Cai for constructive comments. This research was partially supported by the US NIH Grants for I2B2, AIDS, Heart Lung and Blood and General Medical Sciences.
PY - 2013/10
Y1 - 2013/10
N2 - Suppose that we need to classify a population of subjects into several well-defined ordered risk categories for disease prevention or management with their "baseline" risk factors/markers. In this article, we present a systematic approach to identify subjects using their conventional risk factors/markers who would benefit from a new set of risk markers for more accurate classification. Specifically for each subgroup of individuals with the same conventional risk estimate, we present inference procedures for the reclassification and the corresponding correct re-categorization rates with the new markers. We then apply these new tools to analyze the data from the Cardiovascular Health Study sponsored by the US National Heart, Lung, and Blood Institute. We used Framingham risk factors plus the information of baseline anti-hypertensive drug usage to identify adult American women who may benefit from the measurement of a new blood biomarker, CRP, for better risk classification in order to intensify prevention of coronary heart disease for the subsequent 10 years.
AB - Suppose that we need to classify a population of subjects into several well-defined ordered risk categories for disease prevention or management with their "baseline" risk factors/markers. In this article, we present a systematic approach to identify subjects using their conventional risk factors/markers who would benefit from a new set of risk markers for more accurate classification. Specifically for each subgroup of individuals with the same conventional risk estimate, we present inference procedures for the reclassification and the corresponding correct re-categorization rates with the new markers. We then apply these new tools to analyze the data from the Cardiovascular Health Study sponsored by the US National Heart, Lung, and Blood Institute. We used Framingham risk factors plus the information of baseline anti-hypertensive drug usage to identify adult American women who may benefit from the measurement of a new blood biomarker, CRP, for better risk classification in order to intensify prevention of coronary heart disease for the subsequent 10 years.
KW - Coronary heart disease
KW - Nonparametric functional estimation
KW - Risk factors/markers and pointwise
KW - Simultaneous confidence intervals
KW - Subgroup analysis
UR - http://www.scopus.com/inward/record.url?scp=84886585591&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84886585591&partnerID=8YFLogxK
U2 - 10.1007/s10985-013-9272-6
DO - 10.1007/s10985-013-9272-6
M3 - Article
C2 - 23807696
AN - SCOPUS:84886585591
SN - 1380-7870
VL - 19
SP - 547
EP - 567
JO - Lifetime Data Analysis
JF - Lifetime Data Analysis
IS - 4
ER -